New drug tested to stop hives from cold
NCT ID NCT04681729
Summary
This study tested if the drug dupilumab could help people with cold urticaria, a condition where cold temperatures cause itchy hives. It involved 82 people aged 12-80 who still had symptoms even while taking standard antihistamine medications. Participants received either dupilumab or a placebo injection for 24 weeks to see if it could better control their reactions to cold.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLD URTICARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allergy & Asthma Specialists, PSC-Site Number:8400003
Owensboro, Kentucky, 42301, United States
-
Allergy and Asthma Medical Group and Research Center-Site Number:8400001
San Diego, California, 92123, United States
-
Bernstein Allergy Group Inc-Site Number:8400004
Cincinnati, Ohio, 45231, United States
-
Investigational Site Number :0320001
CABA, Buenos Aires, C1023AAB, Argentina
-
Investigational Site Number :0320002
Rosario, Santa Fe Province, 2000, Argentina
-
Investigational Site Number :0320003
Buenos Aires, C1121ABE, Argentina
-
Investigational Site Number :0320004
San Miguel de Tucumán, Tucumán Province, T4000AXL, Argentina
-
Investigational Site Number :0320005
CABA, Buenos Aires, C1181ACH, Argentina
-
Investigational Site Number :0320006
CABA, Buenos Aires, C1414AIF, Argentina
-
Investigational Site Number :1240001
Toronto, Ontario, M3B 3S6, Canada
-
Investigational Site Number :1240002
Québec, G1V 4W2, Canada
-
Investigational Site Number :1240005
Saint-Charles-Borromée, Quebec, J6E 2B4, Canada
-
Investigational Site Number :1240006
Sherbrooke, Quebec, J1L 0H8, Canada
-
Investigational Site Number :1240007
Hamilton, Ontario, L8L 3C3, Canada
-
Investigational Site Number :1240008
Edmonton, Alberta, T5J 3S9, Canada
-
Investigational Site Number :1240009
Hamilton, Ontario, L8S1G5, Canada
-
Investigational Site Number :1240010
Edmonton, Alberta, T6G 1C3, Canada
-
Investigational Site Number :1240011
Montreal, Quebec, H4A 3T2, Canada
-
Investigational Site Number :2760001
Mainz, 55131, Germany
-
Investigational Site Number :2760002
Berlin, 10117, Germany
-
Investigational Site Number :2760004
Dresden, 01307, Germany
-
Investigational Site Number :2760005
Leipzig, 04103, Germany
-
Investigational Site Number :2760006
Hanover, 30625, Germany
-
Investigational Site Number :2760007
Erlangen, 91054, Germany
-
Investigational Site Number :3920002
Nagoya, Aichi-ken, 454-8509, Japan
-
Investigational Site Number :3920003
Hiroshima, Hiroshima, 734-8551, Japan
-
Investigational Site Number :3920007
Sakai-shi, Osaka, 593-8324, Japan
-
Investigational Site Number :3920008
Kamimashiki Gun, Kumamoto, 861-3106, Japan
-
Investigational Site Number :3920009
Habikino-Shi, 583-0872, Japan
-
Investigational Site Number :3920010
Koto-ku, Tokyo, 136-0074, Japan
-
Investigational Site Number :3920011
Tachikawa-shi, Tokyo, 190-0023, Japan
-
Johns Hopkins University (Asthma and Allergy Center)-Site Number:8400005
Baltimore, Maryland, 21224, United States
-
Treasure Valley Medical Research-Site Number:8400007
Boise, Idaho, 83706, United States
Conditions
Explore the condition pages connected to this study.